Despite the promising advances in novel cancer therapy such as immune checkpoint inhibitors (ICIs), limitations including therapeutic resistance and toxicity remain. In recent years, the relationship between gut microbiota and cancer has been extensively studied. Accumulating evidence reveals the role of microbiota in defining cancer therapeutic efficacy and toxicity. Unlike host genetics, microbiota can be easily modified via multiple strategies, including faecal microbiota transplantation (FMT), probiotics and antibiotics. Preclinical studies have identified the mechanisms on how microbes influence cancer treatment outcomes. Clinical trials have also demonstrated the potential of microbiota modulation in cancer treatments. Herein, we review the mechanistic insights of gut microbial interactions with chemotherapy and ICIs, particularly focusing on the interplay between gut bacteria and the pharmacokinetics (eg, metabolism, enzymatic degradation) or pharmacodynamics (eg, immunomodulation) of cancer treatment. The translational potential of basic findings in clinical settings is then explored, including using microbes as predictive biomarkers and microbial modulation by antibiotics, probiotics, prebiotics, dietary modulations and FMT. We further discuss the current limitations of gut microbiota modulation in patients with cancer and suggest essential directions for future study. In the era of personalised medicine, it is crucial to understand the microbiota and its interactions with cancer. Manipulating the gut microbiota to augment cancer therapeutic responses can provide new insights into cancer treatment.
- enteric bacterial microflora
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Emerging evidence has shown the critical role of gut microbiota in modulating cancer treatment outcomes especially in chemotherapy and immunotherapy.
The gut microbiota has extremely complex interactions with cancer drugs by means of pharmacokinetics (eg, metabolism, enzymatic degradation) and pharmacodynamics (eg, immunomodulation).
Meanwhile, cancer therapy can alter the microbiota composition, creating bidirectional interactions.
The gut microbiota has the potential to be a predictive biomarker for cancer treatment responses, which can be useful in guiding the selection of appropriate cancer treatments.
Microbiota modulation, including antibiotics, probiotics, prebiotics, dietary modulation and faecal microbiota transplantation, has shown potential in optimising cancer treatment outcomes.
The gut microbiota can be more easily modified compared with host genetics and is expected to play a vital role in next-generation personalised medicine.
Future research should identify a consortium of microbes with remarkable influence on cancer treatments as well as an optimised approach for microbiota modulation.
Human microbiota is a dynamic collection of 40 trillion microbes, with 3000 species encompassing bacteria, fungi and viruses. They mainly inhabit the epithelial surfaces especially the GI tract.1 2 The gut microbiota orchestrates broad aspects of physiological functions, including nutritional responses and intestinal and immune system homeostasis.3–5 Dysbiosis, the microbiota compositional shift with disrupted homeostasis, is associated with diseases including GI, neurological and metabolic disorders.5 6 Specific gut microbes have also been linked to the pathogenesis of cancers, particularly GI malignancies.7 8 For instance, the Fusobacterium nucleatum antigen adhesin A (FadA) promotes colorectal cancer (CRC) via E-cadherin-Wnt-β-catenin signalling; genotoxin colibactin from polyketide synthase (PKS-positive Escherichia coli enhances colorectal tumourigenesis; and Bacteroides fragilis toxin generates reactive oxygen species (ROS), causing DNA damage.8–11 While these bacteria have direct effects on tumourigenesis, some microbes promote inflammation or weaken immunosurveillance to indirectly facilitate cancer development. These microbial immunomodulatory activities are referred to as the ‘immune-oncology-microbiome axis’.1
Beyond pathogenesis, the microbiota also modulates cancer treatment responses. Despite the rapid development in cancer therapy, challenges remain—acquired resistance, adverse effects and heterogeneous treatment outcomes. Pharmacogenomics is at the forefront of scientific research studying the impact of genetic variants on individual pharmacological responses.12 However, pharmacogenomics cannot fully elucidate the interindividual disparity in drug responses, implying the presence of other contributors.13 Since the gut microbiota is considered as the second genome in humans, the concept of ‘pharmacomicrobiomics’ has been proposed to explain the unsolved questions of pharmacogenomics. Pharmacomicrobiomics focuses on the interplay between gut microbiota and drug response through alterations in pharmacokinetics (ie, modification of drug absorption, distribution, metabolism or elimination) or pharmacodynamics (ie, modification of drug targets or biological pathways leading to varying sensitivity to pharmacological effects).12 Growing evidence has revealed the intimate relationship between the gut microbiota and anticancer treatments, including chemotherapy,14 radiotherapy,15 targeted therapy16 and immunotherapy.1 Harnessing the microbiota to optimise cancer treatments has become an alternate avenue for personalised medicine.
Here, we review the pharmacomicrobiomic interactions between the bacterial component of microbiota and chemotherapy or immune checkpoint inhibitors (ICIs). We highlight the mechanistic insights of microbial influences on anticancer agents in terms of pharmacokinetics and pharmacodynamics. The translational potential of these basic findings is also explored. We further discuss the current limitations in cancer pharmacomicrobiomics and suggest feasible future directions.
Microbiota and chemotherapy
Alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors and cytotoxic antibiotics are chemotherapies with different mechanisms of action. Their anticancer activities rely on disrupting DNA integrity, enzymes for DNA repair and synthesis. However, chemotherapy also damages normal cells due to its non-specificity.17 Recent findings have suggested that targeting microbiota could be promising to improve chemotherapeutic efficacy and reduce toxicity (table 1). Generally, commensal microbes interact with chemotherapeutics mainly by modulating drug metabolism (ie, pharmacokinetics) and host immunity (ie, pharmacodynamics).
Gut bacteria and pharmacokinetics of chemotherapy
Having millions of protein-coding genes, gut bacteria can not only process ingested nutrients but also alter drug pharmacokinetics.18 Microbes-mediated drug metabolism can be divided into direct or indirect interactions.18 Microbes can directly convert drugs into active, inactive or even toxic metabolites. Alternatively, this process can be indirectly mediated by microbes-derived metabolites.18 Here, how bacterial metabolism affects chemotherapeutic outcomes is discussed.
Irinotecan (CPT-11), a topoisomerase I inhibitor, is effective against various cancers and has been the first-line treatment for metastatic CRC.19 20 Mechanistically, tissue and serum carboxylesterase activates intravenous CPT-11 into metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), which then inhibits topoisomerase I to stop DNA replication and transcription of tumour cells.19 The major downside of CPT-11 is its dose-limiting side effect of severe diarrhoea occurring in up to 40% of patients.19 SN-38 is detoxified into SN-38G by liver uridine diphosphate–glucuronosyltransferase before being excreted to the intestine,21 where bacterial β-glucuronidase could convert SN-38G back to cytotoxic SN-38, causing severe diarrhoea22 (figure 1A). While Clostridium clusters XIVa and IV (including Clostridium, Eubacterium and Ruminococcus) are major producers of β-glucuronidase,23 24 CPT-11 could increase the abundance of Clostridium and Enterobacteriaceae in rat, indicating that CPT-11 itself enhances bacterial β-glucuronidase activity.25 A logical question to ask here is whether β-glucuronidase could be inhibited to reduce CPT-11 toxicity. Selective β-glucuronidase inhibitors have now been developed to prevent CPT-11-induced microbial alteration and epithelial damage.26 For example, pyrazolo[4,3-c]quinoline derivatives (TCH-3562) and uronic isofagomine derivatives could reduce CPT-11-induced complications without impairing its efficacy.27–29 Reducing CPT-11 toxicity could in turn increase patients’ tolerance to higher dosage, leading to better therapeutic outcomes.30 This example illustrates the reciprocal interactions between commensal bacteria and chemotherapy, demonstrating the potential of microbiota modulation in reducing therapeutic toxicity and enhancing efficacy.
Beyond drug toxicity, bacterial metabolism is essential to drug effects. Recent studies using Caenorhabditis elegans models have identified bacterial genes mediating chemotherapeutic efficacy especially those involved in ribonucleotide and vitamin B6 and B9 metabolism.31 32 Mechanistically, bacterial ribonucleotide metabolism is required to activate 5-fluorouracil (5-FU) into cytotoxic 5-fluorouridine triphosphate for exhibiting its RNA-damaging effects in C. elegans 31 32 (figure 1B). Disruption of bacterial vitamin B6 and B9 production, which is linked to ribonucleotide metabolism, diminishes 5-FU efficacy, thus implicating the influence of bacterial metabolites on chemotherapeutics.31 Notably, the antidiabetic drug metformin could inhibit the bacterial one-carbon metabolism which is needed for 5-FU to exhibit its anticancer effects, causing reduction of 5-FU efficacy.31 Therefore, special caution is necessary when using chemotherapy in patients with cancer with comorbidity.
Microbes are present intratumorally which can modulate chemotherapeutic efficacy via enzymatic reactions33 34 (figure 1C). Gemcitabine is a nucleoside analogue for treatment of pancreatic ductal adenocarcinoma (PDAC). However, gemcitabine chemoresistance is common in PDAC, which was initially suspected to be caused by the enzyme cytidine deaminase (CDD) of tumour-infecting Mycoplasma hyorhinis.35 Later, scientists discovered that only the long isoform of bacterial CDD (CDD-L) but not the short isoform (CDD-S) could metabolise gemcitabine into inactive metabolite 2’,2’-difluorodeoxyuridine. More than 98% of bacterial species with CDD-L are Gammaproteobacteria, which are commonly enriched in PDAC tumour tissues.36 Yet M. hyorhinis carries CDD-S but still confers gemcitabine resistance, suggesting that contributors other than CDD isoforms also cause chemoresistance. Notably, an exciting translational finding is that coadministration of antibiotic ciprofloxacin could reverse gemcitabine chemoresistance in mice.36 However, current studies mainly focus on the interplay between intratumoral microbiota and chemoresistance, while how gut microbes influence the intratumoral microbiota composition remains elusive.37 38 It is still uncertain about how these microbes enter tumours and the microbial biomass required to inactivate gemcitabine. More preclinical studies are required before translating mechanistic findings into clinical applications.
Gut bacteria and pharmacodynamics of chemotherapy
Beyond pharmacokinetics, the gut microbiota can alter patients’ sensitivity and response to chemotherapy (ie, pharmacodynamics) via immunomodulation. Apart from cytotoxic effects, chemotherapeutics such as cyclophosphamide (CTX) also stimulate anticancer immunity.17 Here, how the immunomodulation of gut bacteria influences chemotherapeutic efficacy is explored.
CTX, an alkylating chemotherapeutic agent, induces anticancer immunity by depleting immunosuppressive T regulatory cells (Treg) and promoting T helper (Th)-1 cell differentiation.17 CTX also modifies the gut microbiota to bolster its immunomodulatory effects. It shortens the intestinal villi in mice to increase intestinal permeability for the translocation of Enterococcus hirae and Lactobacillus johnsonii into secondary lymphoid organs.39 Such translocation accumulates ‘pathogenic’ Th17 and memory Th1 cells, which are essential for CTX-induced anticancer immune response.39 E. hirae also increases the intratumoral CD8+ T cells to CD4+ Treg ratio and even reverses CTX chemoresistance in antibiotics-treated mice40 (figure 1D). In contrast, Barnesiella intestinihominis is not translocated but accumulates in the colon to stimulate systemic polyfunctional CD8+ cytotoxic T cells and Th1 cells, promoting intratumoral infiltration of interferon (IFN)-γ-producing γδT cells.40 41 Notably, these bacterial anticancer effects are limited by the pattern recognition receptor nucleotide-binding oligomerisation domain-containing 2 (NOD2), suggesting the possibility of combining NOD2-targeted therapy with CTX to optimise treatment responses.
Oxaliplatin and cisplatin are platinum-based antineoplastic drugs. Their early cytotoxic effects rely on ROS production, which is dependent on an intact microbiota. Gut microbes especially Gram-positive bacteria modulate myeloid differentiation primary response 88 (MYD88)-dependent signalling pathway to prime intratumoral myeloid cells for ROS generation in response to oxaliplatin42 43 (figure 1E). Similarly, the gut bacteria also mediate their late immunomodulatory effects. Oxaliplatin-induced anticancer immune response requires both the antigenicity from oxaliplatin-induced apoptosis and immunogenic gut commensals.44 Immunogenic bacteria, including non-enterotoxigenic B. fragilis and Erysipelotrichaceae, stimulate migratory dendritic cells (DCs) to signal follicular T helper (TFH) cells via interleukin (IL) 1β and IL-12. Stimulated TFH cells then interact with B cells to increase IgG2b response, enhancing the anticancer effector/memory CD8+ T cell activity. However, these immune responses are significantly reduced in the absence of immunogenic gut commensals44 (figure 1F). Besides direct interactions with immune cells, anticancer immunity can also be modulated by metabolites.45 46 For example, short-chain fatty acids (SCFAs), particularly butyrate, could inhibit histone deacetylases to increase expression of the DNA transcription regulator inhibitor of DNA binding 2 (ID2). ID2 then boosts the cytotoxic function of CD8+ T cells via IL-12 signalling to promote oxaliplatin-induced anticancer immune response46 (figure 1G).
Meanwhile, microbial immunomodulation is also involved in chemoresistance and therapeutic toxicity. F. nucleatum, which is highly enriched in patients with CRC, not only promotes colorectal tumourigenesis11 but also induces chemoresistance to oxaliplatin and 5-FU. It activates toll-like receptor (TLR)-4/MYD88-dependent pathway and inhibits microRNA to switch CRC cells from apoptosis to autophagy. This in turn promotes CRC cell survival under chemotherapy47 (figure 1H). Moreover, the gut microbiota also contributes to mechanical hyperalgesia, a dose-limiting complication of oxaliplatin. Although the mechanism is not fully characterised, hyperalgesia is in part mediated by the interactions between bacterial lipopolysaccharide and macrophage TLR4.48
The host–microbes–drug interactions affecting chemotherapeutic efficacy and toxicity are extremely complex. Even different strains of a bacterial species could have distinct effects, as exemplified by enterotoxigenic and non-enterotoxigenic B. fragilis, of which the former promotes CRC while the latter enhances oxaliplatin efficacy.44 49 Simultaneously, chemotherapy can alter microbiota composition, leading to great disparity in interactions between microbes and drugs among different cancers and individuals. Altogether, these studies have shown the indispensability of gut microbiota to chemotherapy. The impact of concurrent antibiotic use on chemotherapy and the translational potential of these basic findings are worth further investigations.
Preclinical studies have provided mechanistic basis of how microbes affect chemotherapy. Some of these findings have been validated in human association studies, showing that certain microbial signatures are correlated with treatment responses, prognosis or incidence of adverse effects. These findings suggest the feasibility of using microbes as predictive biomarkers.
The relationship between CDD-L and gemcitabine chemoresistance is well established.36 As CDD-L is mainly found in Gram-negative bacteria, a clinical study demonstrated the potential of using intratumoral lipopolysaccharide, a cell wall component of Gram-negative bacteria, to be a negative predictor of gemcitabine efficacy in PDAC.50 Meanwhile, F. nucleatum-induced chemoresistance in mice could be conserved in human patients with CRC. Enrichment of intratumoral F. nucleatum is associated with shorter recurrence-free survival, and its abundance alone has higher accuracy than the American Joint Committee on Cancer staging in predicting CRC recurrence.47 In contrast, E. hirae-specific and B. intestinihominis-specific Th1 immune responses are correlated with improved progression-free survival (PFS) in chemotherapy-treated patients.40 Currently, the potential use of microbes, metabolites or enzymes in treatment outcome prediction is being extensively investigated, such as examining β-glucuronidase level to predict CPT-11-induced toxicity.51
Gut microbiota modulation
Concurrent antibiotic use is commonly applied to prevent opportunistic infection due to chemotherapy-induced immunosuppression.52 However, antibiotics can change the microbial community, which in turn alters chemotherapeutic effects. As intratumoral bacterial CDD-L confers gemcitabine chemoresistance,36 several retrospective clinical studies reported that antibiotics targeting the CDD-L-producing bacteria improve gemcitabine response in patients with PDAC.53–55 Notably, most of these association studies did not involve the collection of tumour samples; thus, how the intratumoral microbiota is altered by antibiotics remains undetermined.
Current studies on antibiotics and chemotherapy have yielded conflicting results. Pflug et al 56 found that patients with chronic lymphocytic leukaemia or relapsed lymphoma receiving CTX/cisplatin and antibiotics concurrently have significantly lower PFS and overall survival (OS). Observational studies in patients with head and neck57 or oesophageal cancer58 also yielded similar results. In general, antibiotic use in chemotherapy could be a double-edged sword. While it is essential in immunocompromised patients, antibiotics may induce gut dysbiosis, causing unfavourable chemotherapy outcomes. Several important questions should be addressed in future studies concerning antibiotics and chemotherapy: do antibiotics simultaneously remove beneficial microbes, leading to suboptimal responses? how can the risks and benefits of using prophylactic antibiotics in patients with cancer be balanced? is antibiotics a safe and effective way to modulate gut microbiota for optimal treatment response? Alternatively, more differentiated strategies could be applied, such as using selective antibiotics guided by antimicrobial susceptibility testing instead of prescribing broad-spectrum antibiotics.57
Another way to modify microbiota is supplementing probiotics, which are live microbes primarily containing Lactobacillus and Bifidobacterium species. Both preclinical59 60 and clinical61 62 data have demonstrated that probiotics could improve chemotherapy outcomes.63 A randomised controlled trial showed that Bifidobacterium-based and Lactobacillus-based probiotics could reduce β-glucuronidase activity to decrease the incidence of CPT-11-induced diarrhoea.64 The probiotic Clostridium butyricum could reduce chemotherapy-induced diarrhoea among patients with lung cancer.65 However, these studies only included small cohorts yielding inconclusive results. Subsequent meta-analyses on clinical trials reported that there is insufficient evidence supporting probiotic use in preventing chemotherapy-induced diarrhoea.64 66 67 The small cohort size, the short duration of study and the presence of confounders inherent to study design are common limitations in current investigations. Although these studies demonstrated the safety of probiotic use, potential risks including bacteraemia should not be neglected in critically ill patients.68 Future studies should evaluate the optimal formula of probiotics, ensure their efficacy in large cohorts and standardise research methods to facilitate comparison across clinical trials.
Prebiotics are substrates selectively used by microbes conferring health benefits which also modulate gut microbiota composition.69 Preclinical studies discovered that prebiotics inulin and oligofructose could potentiate the cytotoxic effects of 5-FU and CTX,70 71 while oatbase72 and pectin73 could reduce methotrexate-induced enterocolitis. Theoretically, prebiotic consumption may selectively enrich beneficial probiotics, including Bifidobacterium and Lactobacillus, and increase SCFA production. Recent studies confirmed that dietary fibres supplementation increases the abundance of Bifidobacterium, Lactobacillus and faecal butyrate concentration in healthy adults.74 However, the exact mechanisms of how prebiotics augment chemotherapy outcomes remains elusive. The durability of prebiotics should also be explored. Prebiotics usually take 1–2 weeks to alter microbiota composition, but the changes may be short-lived on resumption of normal nutritional intake.74 75 A clinical trial on patients with gynaecological cancer showed that taking prebiotics 1 week before to 3 weeks after radiotherapy could improve post-treatment stool consistency.76 However, clinical studies on the effects of prebiotics on chemotherapy are lacking. Another concern to note is the safety issue. Some oligosaccharides could indeed double the β-glucuronidase activity, aggravating CPT-11-induced toxicity in mice.77 Future investigations are warranted to address the clinical safety of prebiotics.
Microbiota and ICIs
Resistance and recurrence are common problems of chemotherapy.78 Since the last decade, the rapid development of immunotherapy has reshaped clinical guidelines in oncology. Generally, tumour cells develop mechanisms to evade immunosurveillance, the host immunity for tumour eradication.79 80 Tumour cells could express programmed death-ligand 1 (PD-L1) that binds to programmed cell death protein-1 (PD-1) on T cells, causing their inactivation. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is another immune checkpoint on T cells which leads to T cell inactivation on ligand binding.79 81–83 To reverse immunosuppression, anti-PD-1/PD-L1 and anti-CTLA-4 monoclonal antibodies (mAbs) have been introduced. Promising results from landmark clinical trials84–86 have led to the United States Food and Drug Administration (FDA) approval of different ICIs for cancer treatment.
Nevertheless, the major challenges facing immunotherapy include the interpatient heterogeneity of ICI responses87–89 and the immune-related adverse events (irAEs), especially colitis in anti-CTLA-4 mAbs and pneumonitis in anti-PD-1/PD-L1 mAbs.90–92 Given the intricate interplay between the gut microbiota and host immunity, growing evidence has illustrated the potential application of microbiota modulation in optimising immunotherapy responses (figure 2). Generally, commensal microbes interact with ICIs by altering pharmacodynamics, particularly immunomodulation, rather than pharmacokinetics.
Gut bacteria and anti-CTLA-4 mAbs
Preclinical studies have illustrated the indispensable role of gut microbiota in immunotherapy efficacy93 94 (table 2). A pioneering study in 2015 demonstrated how gut bacteria influence the anti-CTLA-4 mAbs effects in mice.93 Anti-CTLA-4 mAbs induce B. fragilis, B. thetaiotaomicron and Burkholderia cepacia to grow in the intestinal mucosa. These bacteria, particularly B. fragilis, then produce polysaccharides to stimulate CD11b+ DCs in the lamina propria, improving IL-12-dependent Th1 immune response in tumour-draining lymph nodes (figure 2A). Meanwhile, microbiota-depleted mice have impaired response to anti-CTLA-4 mAbs, signifying the importance of microbiota in immunotherapy. Interestingly, recolonisation of B. fragilis and B. cepacia in bacteria-depleted mice not only rescues their immunotherapeutic resistance but also reduces the histopathological signs of colitis.93 95 Bifidobacterium administration also minimises anti-CTLA-4 mAbs-induced irAEs without compromising its efficacy. Mechanistically, Bifidobacterium enhances the suppressive functions of intestinal Treg through IL-10 mediation.96 97 B. bifidum cell surface β-glucan/galactan polysaccharides also induce Treg by generating regulatory DCs to ameliorate colitis.98
Beyond direct interaction with immune cells, indirect immunomodulation via microbes-derived metabolites is also possible (figure 2C). As anti-CTLA-4 mAbs impair intestinal barrier, metabolite inosine derived from Bifidobacterium pseudolongum and Akkermansia muciniphila could enter the systemic circulation. Inosine then activates Th1 cells via adenosine 2A receptor costimulated by DCs to enhance tumour shrinkage in the presence of ICIs.99 The anticancer effect of inosine may also be attributed to its role as an alternative fuel to glucose for effector T cells within the tumour microenvironment (TME).100
Gut bacteria and anti-PD-1/PD-L1 mAbs
Another pivotal study in 2015 showed that gut bacteria could modulate the efficacy of anti-PD-1/PD-L1 mAbs in mice.94 B. breve and B. longum activate DCs for CD8+ T cell priming and infiltration in TME, enhancing the immunotherapeutic effects.94 Bifidobacterium also mediates innate immunity to potentiate anti-PD-1 mAbs efficacy in melanoma mouse models101 (figure 2B). Mechanically, Bifidobacterium secretes metabolite hippurate and inhibits PD-1 expression, which in turn activates natural killer (NK) cells to destroy tumours via perforin and IFN-γ mediation.101 As Bifidobacterium also mitigates irAEs induced by CTLA-4 blockade,96 it is worth exploring whether Bifidobacterium could simultaneously enhance efficacy and reduce toxicity of combined PD-1/PD-L1 and CTLA-4 blockade.
Probiotic bacteria also modulate immunotherapeutic effects. L. rhamnosus GG (LGG), a well-studied and commonly used probiotics, could reduce CRC occurrence and impede tumour progression of hepatocellular carcinoma in mice.102 LGG also improves anti-PD-1 mAbs effects in mice by increasing tumour-infiltrating DCs and T cells. Mechanistically, LGG promotes IFN-β production by activating STING (stimulator of IFN genes) and its secondary messenger cyclic GMP-AMP synthase (cGAS) to induce phosphorylation of interferon regulatory factor 7. The increased IFN-β production via this cGAS/STING-dependent axis eventually enhances cross-priming of anticancer CD8+ T cells.102 LGG intake also enriches tumour-suppressing B. uniformis and L. murinus in the intestine, of which B. uniformis is associated with the enrichment of IFN-γ+ CD8+ T cells in mesenteric lymph nodes,103 whereas L. murinus is correlated with DC activation in the gut.104
Antigen mimicry between commensal bacteria and tumour cells also confers beneficial responses to ICIs (figure 2C). Apart from activating DCs for T cell priming as aforementioned,94 B. breve antigen SVY is homologous to mouse melanoma SIY neoantigen, thereby stimulating cross-reactive T cell response against melanoma cells.105 Meanwhile, E. hirae-infecting bacteriophage expresses tape measure protein (TMP), which stimulates memory CD8+ T cell response to cross-react with cancer antigen proteasome subunit beta type-4 protein. Administrating bacterial strains expressing TMP epitope could improve immunotherapy efficacy in mice.106 Notably, recent investigations have linked several autoimmune disorders to the molecular mimicry between microbes-derived antigens and self-antigens.107 108 Considering the diversified proteome in the gut microbiota,109 110 more microbial antigens with high homology to cancer antigens would likely be discovered.
Epithelial barrier also plays a role in the microbes-mediated immunomodulation (figure 2D). A study reported the enhanced anticancer immunity in Rnf5 −/− mice with melanoma (RNF5 is a membrane-bound E3 ubiquitin ligase implicated in protein degradation).111 Mechanistically, Rnf5 −/− mice had reduced antimicrobial peptides and increased enterocyte apoptosis, causing enrichment of Bacteroides and Parabacteroides, which together activated DCs to promote intratumoral infiltration of IFN-γ-producing T cells.111 These findings are indeed similar to the oxaliplatin-induced anticancer immune response.44 The antigenicity from oxaliplatin-induced apoptosis and immunogenic gut commensals not only mediate the anticancer immunity of oxaliplatin as aforementioned, but also provide synergistic therapeutic effects when combining oxaliplatin with anti-PD-1 mAbs. Altogether, epithelial injury and immunogenic bacteria stimulate DCs for helper or cytotoxic T cell immune response against cancers.
The microbial interactions with ICIs are complicated. With reference to a previous review proposing the ‘TIMER’ (Translocation, Immunomodulation, Metabolism, Enzymatic degradation, and Reduced diversity and ecological variation) mechanistic framework describing the microbes–chemotherapy interactions,14 we categorise microbes–immunotherapy interactions into a ‘TIME’ framework: T cell mediation, Innate immunity, Metabolites and molecular mimicry, and Epithelial injury (figure 2). Given the complexity, a mechanistic framework can better illustrate the microbes–immunotherapy interactions, which lays the foundation for translating these basic findings to clinical application.
Following the preclinical evidence,93 94 metagenomic studies on patients with melanoma and epithelial tumour in 2018 confirmed the role of gut microbiota in anti-PD-1/PD-L1 mAbs responses112–114 (table 3). Faecalibacterium, B. longum, Collinsella aerofaciens, E. faecium, A. muciniphila and E. hirae were enriched in responders of anti-PD-1 mAbs, while Bacteroides, Ruminococcus obeum and Roseburia intestinalis were enriched in non-responders. Consistently, all three studies demonstrated that faecal microbiota transplantation (FMT) from responders to germ-free mice could potentiate the anti-PD-1 mAbs efficacy. However, the microbes identified from these studies are diverse and have little overlap with one another.112–114 In 2022, a follow-up study was performed to validate the predictive value of A. muciniphila in a prospective multicentric cohort of patients with non-small cell lung carcinoma (NSCLC).115 An interesting distribution was observed: ‘normal’ abundance of A. muciniphila (relative abundance <4.799%) is associated with longer OS, while both the absence and overabundance of A. muciniphila (relative abundance >4.799%) are associated with shorter OS.115 The predictive value of this trichotomic stratification is even more accurate than tumour PD-L1 expression, a clinically used predictive biomarker for ICI response in NSCLC.115 Compared with tumour cells in patients with undetectable faecal A. muciniphila, tumour cells in patients with detectable faecal A. muciniphila have higher gene expression related to T cell activation and IFN fingerprint, which are related to improved anti-PD-1 mAb response.115 These findings are in line with previous mechanistic studies, suggesting that A. muciniphila promotes intratumoral infiltration of Th1 cells.112
Studies on combined anti-PD-1/anti-CTLA-4 immunotherapy in patients with melanoma were also conducted116–118 (table 3). Faecalibacterium prausnitzii, Holdemania filiformis and B. thetaiotaomicron were enriched in responders, while Bacteroides species were enriched in non-responders.116 117 Transcriptomic analysis further showed that sugar degradation pathway, vitamin B biosynthesis pathways and guanosine nucleotide biosynthesis pathways are linked to shorter PFS.116 While Gopalakrishnan et al 114 found that amino acid biosynthesis is enriched in responders, Peters et al specifically identified that L-isoleucine biosynthesis is linked to longer PFS,116 which may be related to its immunomodulatory effects.119
Currently, consensus in the bacterial species associated with immunotherapeutic responses is lacking even in the same cancer type (eg, metastatic melanoma). Possible reasons include the differences in sample collection, sequencing technology and bioinformatics pipelines among studies.120 121 A meta-analysis integrated and reanalysed the data from three previous studies,112–114 concluding that analytical pipelines are not the cause of the interstudy variation.122 Interestingly, there are more overlaps in the microbial gene content rather than the microbiota composition across studies, implying that the signature microbes identified in different studies could be functionally related. Particularly, microbial gene contents provided a higher predictive value than the microbiota composition for assessing treatment response, with an area under curve >0.7, showing the potential of using microbial gene signatures as predictive biomarkers.122 A recent prospective multicentric study validated the positive association of A. muciniphila with improved ICI effects.115 This study demonstrated that faecal samples with detectable A. muciniphila are enriched with immunogenic bacteria identified across numerous studies,112 114 116–118 123 including Ruminococcaceae,114 Lachnospiraceae family116 and B. intestinihominis.123 To date, different studies have identified a variety of microbial species that are associated with ICI response. However, their interactions with one another and which microbes have a more dominant role in ICIs remain unknown. This study therefore provides initial insights that A. muciniphila could be the master regulator of immunogenic bacteria to contribute to the improvement in ICI response.115
Altogether, these studies have illustrated that microbial biomarkers may predict cancer treatment outcomes. Some of the bacteria identified from human studies, including A. muciniphila,112 B. intestinihominis 123 and B. thetaiotaomicron,117 were also mechanistically shown to improve therapeutic response through immunomodulation,40 93 99 further confirming their translational potential. However, a major challenge is the lack of consensus on the signature species across studies, making it difficult to establish a well-acknowledged consortium of microbial biomarkers. To reduce interstudy disparity, the methods of sample collection, sequencing and bioinformatics analysis should be standardised.124 Large cohort studies with multiomics approaches could provide more insights on the correlation between gut microbiota and ICI response. Moreover, further functional investigations and clinical trials are required to explore the translational potential of these observations.
Gut microbiota modulation
Prophylactic antibiotics are commonly used with immunotherapy to prevent life-threatening infections. However, clinical studies observed diminished response to immunotherapy in antibiotics-treated patients,125–127 in line with evidence from preclinical animal studies.93 94 Both retrospective125 127 and prospective126 studies showed that antibiotic use is associated with lower PFS, OS and response rate. The timing of antibiotic use is also important. A meta-analysis reported that patients without antibiotic use 42 days before ICI initiation have 3.43 times longer OS, while no significant difference in OS was observed between patients with and without antibiotic use 60 days before ICI.128 These findings are consistent with a study of healthy individuals treated with an antibiotic cocktail (meropenem, gentamicin and vancomycin) for 4 days, of which their microbiota composition recovered to near-baseline within 42 days.129 Apart from epidemiological observations, recent studies showed that patients with antibiotic use have enriched microbial features associated with poor survival, such as low diversity and enrichment of C. hathewayi.130 131 Antibiotic use should therefore be avoided before ICIs. Alternatively, FMT or probiotics may be plausible option to reverse antibiotics-induced dysbiosis before ICIs. Notably, PDAC could be an exception as preclinical studies have shown that intratumoral bacterial ablation using antibiotics in PDAC improves immunotherapeutic efficacy (figure 2B).132 Hence, the effects of antibiotics or microbiota on cancer therapy should be carefully studied in distinct cancer types.
Modulating immunotherapy response using probiotics is another plausible method. Many microbes associated with improved immunotherapy response, including B. longum and LGG, are indeed commercially available probiotics.94 102 Preclinical studies showed that probiotics could enhance anticancer immunity by reducing Treg level133 and enhancing CD8+ T cell activation, CD4+ T cell differentiation and intratumoral infiltration of NK cells.134 A proof-of-concept study by Tanoue et al 103 reported that a defined consortium of 11 bacterial strains (7 Bacteroidales and 4 non-Bacteroidales species) could enhance ICI efficacy in mice with syngeneic tumours via CD103+ DC-mediated induction of IFN-γ-producing CD8+ T cells. This highlights the feasibility of probiotics as adjuvants to improve immunotherapy outcomes. Clinical trials demonstrated that probiotics B. lactis Bl-04 and L. acidophilus NCFM could increase the abundance of butyrate-producing species, particularly Faecalibacterium and Clostridiales, in the gut of patients with CRC.135 These species were associated with improved immunotherapy response in human patients.114 116–118 However, current clinical investigations only demonstrate the impact of probiotics on gut microbiota but not their direct causative effects on immunotherapeutic outcomes. A recent clinical study even showed that probiotics use is correlated with lower microbial diversity, a common feature in non-responders of immunotherapy.136 Such finding has been recapitulated in a preclinical mechanistic study showing that mice treated with either probiotic B. longum or LGG have worse response to anti-PD-L1 mAbs, with reduced level of intratumoral IFN-γ+ CD8+ T cells.137 These latest results therefore present an opposite picture compared with previous studies. Over-the-counter probiotics should therefore be discouraged in patients receiving immunotherapy as current understandings are still limited.
Prebiotics and dietary modulation are alternatives to augment ICI responses. Common prebiotics such as inulin and galacto-oligosaccharide could raise the abundance of Bifidobacterium, Lactobacillus and Faecalibacterium species in human gut,138 139 which are immunogenic bacteria associated with improved anticancer immunity.93 94 103 However, studies demonstrating the direct effects of prebiotics on ICIs are lacking, which warrant further investigations. On the other hand, dietary modulation was shown to be effective in augmenting therapeutic effects. High-fibre diet in patients with metastatic NSCLC receiving ICIs is associated with enrichment of Bifidobacterium species and better clinical outcomes.140 Patients with melanoma with high-fibre intake also had improved ICI response.137 This is supported by a parallel mechanistic study demonstrating the increased level of tumour-infiltrating lymphocytes in ICI-treated mice fed with high-fibre diet, of which the enrichment of fibre-fermenting Ruminococcaceae family after fibre supplementation could promote T cell activation and intratumoral infiltration.137 Another example is that the ketone body 3-hydroxybutyrate produced by ketone diet could enhance ICI efficacy in mice. 3-Hydroxybutyrate increases the expansion of ICI-induced CD8+ T cells and restrains PD-L1 expression to maintain T cell activation for anticancer effects.141 Ketone diet could enrich Eisenbergiella massiliensis in human gut, which is strongly correlated with serum 3-hydroxybutyrate concentration.141 However, the gut microbiota responds rapidly to dietary changes, implicating the short-lived effects of dietary modulation.75 Maintaining a new diet is notoriously difficult; hence, how to retain and prolong dietary effects to improve ICI response requires further investigations.
FMT is another clinical approach of microbiota modulation which has received FDA approval for treating recurrent C. difficile infection.142 FMT is the transfer of entire faecal microbial community, including bacteria, viruses, fungi and their metabolites, from a healthy donor into the recipient.142 Wang et al 143 reported the first case of treating immunotherapy-induced colitis using FMT. Normally, ICI-induced colitis is treated with immunosuppressive agents including corticosteroids, which nonetheless have considerable side effects. In this study, the two patients with ICI-induced colitis were refractory to conventional therapy but showed significant improvement after FMT with enrichment of beneficial Bifidobacterium species. Nevertheless, future clinical trials are required to validate the translational potential of FMT in immunotherapy due to the pioneering nature of this initial study.
Meanwhile, two recent proof-of-concept clinical trials demonstrated the safety and efficacy of FMT in boosting anti-PD-1 mAbs response in patients with refractory melanoma.144 145 Baruch et al 144 recruited 12 patients with melanoma composing of 10 non-responders and 2 responders to ICIs. The 10 non-responders were treated with antibiotics for microbiota depletion, followed by FMT with stools from the 2 responders and reintroduction of anti-PD-1 mAbs. Two patients showed partial response while one showed complete response, suggesting a true de novo immunotherapeutic response. Similarly, Davar et al 145 treated 15 patients with ICI-refractory melanoma with FMT (stools from responders) and anti-PD-1 mAbs. Three patients showed objective response, while another three patients showed stable disease. Both studies have demonstrated the causative effects of FMT on immunotherapy response, implicating the clinical safety and feasibility of FMT in cancer treatment. Unlike other modulation methods, the effects of FMT on gut microbiota could persist for more than 24 weeks with less requirement for frequent interventions.142 Indeed, in the study by Davar et al FMT was performed only once each patient.145 Additionally, future studies should consider using ICI biomarkers including PD-L1 expression and tumour mutation burden to assess whether a pre-existing adaptive immunity is essential for effective FMT.146
Future perspectives and conclusion
Therapeutic resistance and toxicity are major stumbling blocks in cancer therapy. Tremendous efforts have been put to predict treatment outcomes and optimise treatment response.147 Gut microbes are undeniably potential candidates for being predictive biomarkers and treatment targets. Despite the current exciting results, the future is not without challenges (table 4). These include inadequate mechanistic understanding of microbiota modulation on therapeutic response, undetermined microbial signatures as biomarkers and the lack of consensus on the optimal microbiota modulation method. Moreover, current studies focus mainly on bacteria, but commensal viruses, fungi and archaea also have unneglectable role in cancers.148–150 Of note, FMT transfers not only bacteria but also other non-bacterial microbes, yet their effects on recipients are unclear, which raises potential safety concerns.
Concerted efforts are required to overcome challenges lying ahead. First, more functional investigations and prospective longitudinal human studies are needed to dissect the biological complexity of host–microbes–drug interactions. Rigorous identification of the key microbes affecting treatment outcome is the prerequisite for clinical translation. Future studies should go beyond bacteria. A recent study demonstrated that depleting gut bacteria could lead to commensal fungi overgrowth, reducing the radiotherapy-induced anticancer immunity. Interestingly, depleting commensal fungi could enhance radiotherapy efficacy, suggesting the antagonistic roles of gut bacteria and fungi in anticancer immunity. Interkingdom interactions of microbiota in cancer therapy are therefore an important future direction.15 Second, metagenomic studies should be standardised and integrated with other ‘omics’, including transcriptomics and metabolomics. Technological advancements such as capsule endoscopy also enable analysis of microbiota along different regions of the gut.151 Together, these would provide insights on the mechanistic basis of host–microbes–drug interactions. Finally, the best approach of microbiota modulation for augmenting treatment outcomes should be determined. Future clinical trials should assess the efficacy, durability and safety of different methods including probiotics, prebiotics, antibiotics and FMT. Other innovative methods are recently reported, such as using bacteriophages to target specific microbes152 or engineered microbes for drug delivery and tumour lysis.153 154 Yet again extensive work is required before clinical translation. It is expected that many more mysteries of human microbiota will be unravelled with the efforts from scientists and clinicians, which will pave the way to next-generation personalised medicine.
Patient consent for publication
This study does not involve human participants.
Contributors NL-NT collected the data and drafted the manuscript. HCHL revised the manuscript. JY supervised and revised the manuscript.
Funding This study was supported by the National Key R&D Program of China (no: 2020YFA0509200/2020YFA0509203), RGC Theme-based Res Scheme Hong Kong (T21-705/20-N), RGC Collaborative Research Fund (C4039-19GF, C7065-18GF), RGC-GRF Hong Kong (14163817), and Vice-Chancellor’s Discretionary Fund Chinese University of Hong Kong.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.